S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
NASDAQ:TTOO

T2 Biosystems Stock Forecast, Price & News

$0.87
-0.01 (-1.13 %)
(As of 10/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.86
$0.89
50-Day Range
$0.82
$1.07
52-Week Range
$0.81
$3.79
Volume2.36 million shs
Average Volume6.60 million shs
Market Capitalization$144.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
30 days | 90 days | 365 days | Advanced Chart
Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems logo

About T2 Biosystems

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTOO
Employees
148
Year Founded
N/A

Sales & Book Value

Annual Sales
$18.13 million
Book Value
$0.06 per share

Profitability

Net Income
$-46.80 million
Net Margins
-166.02%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$144.62 million
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

841st out of 1,360 stocks

Surgical & Medical Instruments Industry

85th out of 124 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

Is T2 Biosystems a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" T2 Biosystems stock.
View analyst ratings for T2 Biosystems
or view top-rated stocks.

What stocks does MarketBeat like better than T2 Biosystems?

Wall Street analysts have given T2 Biosystems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but T2 Biosystems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 8,670,000 shares, an increase of 26.9% from the August 31st total of 6,830,000 shares. Based on an average trading volume of 3,570,000 shares, the days-to-cover ratio is currently 2.4 days.
View T2 Biosystems' Short Interest
.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for T2 Biosystems
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings data on Thursday, August, 5th. The medical equipment provider reported ($0.08) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.08). The medical equipment provider earned $6.69 million during the quarter, compared to the consensus estimate of $5.97 million. T2 Biosystems had a negative trailing twelve-month return on equity of 510.02% and a negative net margin of 166.02%.
View T2 Biosystems' earnings history
.

How has T2 Biosystems' stock been impacted by Coronavirus?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TTOO stock has increased by 76.2% and is now trading at $0.8720.
View which stocks have been most impacted by COVID-19
.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24 million-$26 million, compared to the consensus revenue estimate of $25.23 million.

What price target have analysts set for TTOO?

4 Wall Street analysts have issued twelve-month price targets for T2 Biosystems' shares. Their forecasts range from $1.65 to $3.50. On average, they expect T2 Biosystems' stock price to reach $2.91 in the next twelve months. This suggests a possible upside of 234.0% from the stock's current price.
View analysts' price targets for T2 Biosystems
or view top-rated stocks among Wall Street analysts.

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • John J. Sperzel, Chairman, President & Chief Executive Officer
  • Alec Barclay, Chief Operations Officer
  • John M. Sprague, Chief Financial Officer
  • Roger Smith, Vice President-Science, Research & Development
  • Sandy J. Estrada, Vice President-Medical Affairs

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among T2 Biosystems' employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.08%). Company insiders that own T2 Biosystems stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems
.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was acquired by a variety of institutional investors in the last quarter, including Welch & Forbes LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Adrian M Jones, and Goldman Sachs & Co Llc.
View insider buying and selling activity for T2 Biosystems
or or view top insider-buying stocks.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.87.

How much money does T2 Biosystems make?

T2 Biosystems has a market capitalization of $144.62 million and generates $18.13 million in revenue each year. The medical equipment provider earns $-46.80 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does T2 Biosystems have?

T2 Biosystems employs 148 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

Where are T2 Biosystems' headquarters?

T2 Biosystems is headquartered at 101 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at (781) 761-4646 or via email at [email protected].


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.